Anthem Biosciences Q2 FY27 Financial Results

Revenue: INR 594 crore | EBITDA Margin: 50.6%

Reader Takeaway: Robust operational efficiency and margin expansion drive growth, balanced by inherent clinical trial risks and competitive customer dynamics.

What just happened

Anthem Biosciences released its Q2 FY27 earnings, reporting a consolidated revenue of INR 594 crore. The CRDMO segment remains the primary driver, contributing INR 509 crore, while Specialty Ingredients added INR 85 crore. The company posted an EBITDA of INR 330 crore, representing a significant 50.6% margin. Profit after tax (PAT) for the quarter stood at INR 211 crore.

Why this matters

The results highlight the company's ability to maintain high margins through operational leverage and cost control. With a strong cash position of INR 1,534 crore as of September 30, 2026, Anthem is well-positioned to fund its ambitious expansion plans. The increase in commercial molecules to 15 indicates a successful transition of projects from late-stage development to market, reinforcing the company's role in the global pharmaceutical supply chain.

Capex and Strategic Focus

Management reiterated the INR 1,200 crore capital expenditure plan for the Phase 1 development of the Unit 4 facility. This 30-acre expansion is central to the company’s long-term strategy, which focuses on high-growth segments including oligonucleotides, lipids, ADCs, peptides, and RNAi. Increasing capabilities in biologics manufacturing and fill-finish services remains a top priority.

Risks to watch

Growth is subject to the unpredictability of clinical trial outcomes for the company's 9 late-stage molecules. Additionally, while Anthem is currently a sole supplier for several molecules, management noted that big pharma customers often seek a second supplier once an asset is acquired, which could heighten competitive pressure in the future.

Context metrics

International markets account for 84% of total revenue, with Europe being the largest geography at 60%. Supply chain security has improved, with domestic procurement rising to approximately 78% and reliance on Chinese imports dropping to about 20-21%.